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The ‘Journal of Comorbidity’ is changing its name to the
‘Journal of Multimorbidity and Comorbidity’. This may
seem redundant, as many see ‘comorbidity’ and ‘multimor-
bidity’ as interchangeable terms. We believe it is important
to highlight the distinction given the differences in how
healthcare systems view patients with multiple chronic
conditions (MCCs), and the important differences that arise
in research and intervention development for these patients.
In 1970, Feinstein first coined the term ‘comorbidity’ to
describe ‘Any distinct additional entity that has existed or
may occur during the clinical course of a patient who has
the index disease under study’.1 From 1976,2,3 the term
‘multimorbidity’ was increasingly used by health research-
ers to describe patients with MCCs. Due to the growing
ambiguity around the use of the terms comorbidity and
multimorbidity, in 1996 van den Akker et al. suggested
clear definitions for both terms.4 They suggested that
comorbidity be defined according to Feinstein’s original
definition and multimorbidity be defined as ‘the co-
occurrence of multiple chronic or acute diseases and med-
ical conditions within one person’.4 In 2010, Boyd and
Fortin provided a simpler definition of multimorbidity: ‘the
co-existence of two or more chronic conditions, where one
is not necessarily more central than the others’.5
Healthcare delivery
The distinction of whether a patient with MCCs has an
index disease under study may seem inconsequential. How-
ever, it is important because it reflects the way different
parts of the healthcare system view and interact with
patients who have MCCs. The concept of comorbidity is
more useful in secondary and tertiary care settings, which
have traditionally been structured around diseases or body
systems, while the concept of multimorbidity is more
useful in a primary care or other generalist setting, which
can easily change focus according to patients’ priorities.
For example, a patient with diagnosed chronic kidney dis-
ease, Type 2 Diabetes and hypertension, when seeing their
nephrologist is considered by the specialist to have chronic
kidney disease with comorbidities of Type 2 Diabetes and
hypertension. When seeing their endocrinologist, they are
considered to have Type 2 diabetes with comorbid chronic
kidney disease and hypertension. However, a primary care
physician or other generalist such as a geriatrician would
view the patient as having multimorbidity as they provide
holistic care that is not determined by the presence of any
specific condition and focuses on the patient’s presenting
symptoms, preferences and priorities for their healthcare.
1 Menzies Centre for Health Policy, Sydney School of Public Health,
University of Sydney, Sydney, New South Wales, Australia
2Department of Family Medicine and Emergency Medicine, Universite de
Sherbrooke, Sherbrooke, Quebec, Canada
3 Institute of General Practice, Goethe University, Frankfurt, Germany
4Department of Family Medicine, School CAPHRI, Maastricht University,
Maastricht, The Netherlands
5Academic Centre for General Practice, Department of Public Health and
Primary Care, KU Leuven, Belgium
6General Practice and Primary Care, Institute of Health and Wellbeing,
University of Glasgow, Glasgow, UK
7 Aging Research Centre, Department of Neurobiology, Care Sciences
and Society, Karolinska Institutet and Stockholm University,
Stockholm, Sweden
8 HRB Centre for Primary Care Research, Department of General
Practice, Royal College of Surgeons, Dublin, Ireland
Corresponding author:
Christopher Harrison, Menzies Centre for Health Policy, Sydney School
of Public Health, University of Sydney, Sydney, New South Wales 2006,
Australia.
Email: christopher.harrison@sydney.edu.au
Journal of Multimorbidity and Comorbidity
Volume 11: 1–3





Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open
Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The concept of comorbidity may be more useful for the
development of biomedical knowledge (including pharma-
ceutical research). Most medications and treatments devel-
oped are targeted at treating a specific condition or groups
of similar conditions, though even in disease targeted trial
populations, patients with multimorbidity are generally
underrepresented.6 It can also be appropriate in clinical
practice to focus on single conditions, when this is the
patients’ main priority or source of symptoms, for example,
a patient with existing chronic conditions develops severe
heart failure which, due to its seriousness, becomes the
focus of care, while comorbidities may influence treatment
decisions.7,8
While the concept of comorbidity may be useful to spe-
cialists and some biomedical research, its disease-centric
focus helps cement many health care systems’ single dis-
ease ‘siloed’ structure. This siloed structure may cause
fragmented care for patients with MCCs as different parts
of the health system view the condition they are treating as
the primary condition. Multimorbidity is a more helpful
way to view and assess patients with MCCs because its
focus is on the patient as a whole, aligning with the concept
of patient-centred care. The patient’s experience and prio-
rities, as well as their overall treatment burden, are the
primary focus with no condition being prioritised over any
other.
Comorbidity versus multimorbidity in
research
The distinction between comorbidity and multimorbidity is
also important in research design, especially when it comes
to patient sampling. In many studies, patients are selected
as study participants based on whether they have a specific
diagnosed condition, with their comorbidities being
recorded. While it is true that the patients with comorbidity
in these studies also have multimorbidity, one of the com-
mon errors for secondary analyses of these data sets is to
assume that these patients with MCCs are representative of
all patients with multimorbidity. This is clearly not the case
as the sample would not include multimorbid patients who
do not have the index condition. The representativeness of
the sample is further skewed because certain types of con-
ditions are likely to cluster (as some conditions may share
the same risk factors or underlying physiologic mechan-
ism), meaning that not only will the index condition be
over represented in the sample, but so will conditions that
often co-occur with the index condition. Sampling and
consideration of adequate sample size is particularly impor-
tant when studying the genesis and shared pathways among
concurrent diseases. Unlike the study of comorbidity,
which has dominated most of the aetiological research so
far, a focus on multimorbidity enables the exploration of
potentially causal associations among all coexisting condi-
tions at once. This can identify common patterns and sus-
ceptibility to clusters of co-occurring diseases, whether
these are genetic, biologic, and/or linked to the physical
or social environment
Developing interventions
One of the main challenges for health systems and
researchers is the development and evaluation of interven-
tions to improve outcomes for patients with MCCs. Here
again the distinction between comorbidity and multimor-
bidity is critical. Interventions designed for comorbidity
can specifically target the comorbid conditions and exam-
ine disease-specific outcomes, whereas, interventions for
multimorbidity must have a more generic focus and out-
comes can be challenging to identify.9 A recently devel-
oped core outcome set provides some guidance in this
area.10 The clear reporting of the conditions included in
definitions used for both comorbidity and multimorbidity
is also important to facilitate a consideration of generalisa-
bility of interventions to other patient groups and settings.
Journal of Multimorbidity and
Comorbidity
The name comorbidity was initially chosen for the journal
for its simplicity, comorbidity’s importance for treatment
of specific conditions and acknowledgement of comorbid-
ity’s historical pre-eminence as a construct.11 The addition
of multimorbidity to the journal’s name changes none of
this, but it does acknowledge that this journal is the natural
home for multimorbidity research. Having both concepts
highlighted in the journal’s name emphasises that they are
distinct concepts in research design, intervention develop-
ment and healthcare delivery. Our journal is committed to
publishing high quality research on both comorbidity and
multimorbidity. We look forward to reporting the growing
evidence that addresses critical questions that will aid our
understanding of both comorbidity and multimorbidity and
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